These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

723 related articles for article (PubMed ID: 29464405)

  • 1. The Role of Circulating Tumor DNA in Renal Cell Carcinoma.
    Bergerot PG; Hahn AW; Bergerot CD; Jones J; Pal SK
    Curr Treat Options Oncol; 2018 Feb; 19(2):10. PubMed ID: 29464405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications.
    Hahn AW; Gill DM; Maughan B; Agarwal A; Arjyal L; Gupta S; Streeter J; Bailey E; Pal SK; Agarwal N
    Oncotarget; 2017 May; 8(20):33614-33620. PubMed ID: 28431395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.
    Pal SK; Sonpavde G; Agarwal N; Vogelzang NJ; Srinivas S; Haas NB; Signoretti S; McGregor BA; Jones J; Lanman RB; Banks KC; Choueiri TK
    Eur Urol; 2017 Oct; 72(4):557-564. PubMed ID: 28413127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
    Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L
    Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.
    Khagi Y; Goodman AM; Daniels GA; Patel SP; Sacco AG; Randall JM; Bazhenova LA; Kurzrock R
    Clin Cancer Res; 2017 Oct; 23(19):5729-5736. PubMed ID: 28972084
    [No Abstract]   [Full Text] [Related]  

  • 6. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.
    Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R
    Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
    Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
    Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor DNA (ctDNA) and Its Role in Gynecologic Malignancies.
    Pomerantz T; Brooks R
    Curr Treat Options Oncol; 2024 Apr; 25(4):510-522. PubMed ID: 38472567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
    Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
    Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
    Hicks JK; Saller J; Wang E; Boyle T; Gray JE
    Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer.
    Zhang X; Zhao W; Wei W; You Z; Ou X; Sun M; Yin Y; Tang X; Zhao Z; Hu C; Liu F; Deng J; Mao L; Zhou D; Ren Y; Li X; Zhang S; Liu C; Geng J; Yao G; Song B; Liu Y; Li D; Jiang Y; Chen Y; Zhao Y; Yu S; Pang D
    Clin Cancer Res; 2019 Nov; 25(21):6546-6553. PubMed ID: 31350313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma.
    Kim YJ; Kang Y; Kim JS; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Park D; Park WY; Kang M
    Sci Rep; 2021 Mar; 11(1):5600. PubMed ID: 33692449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
    Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
    Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.
    Scilla KA; Rolfo C
    Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relevance of tumor mutation profiling in interpretation of NGS data from cell-free DNA in non-small cell lung cancer patients.
    Ottestad AL; Wahl SGF; Grønberg BH; Skorpen F; Dai HY
    Exp Mol Pathol; 2020 Feb; 112():104347. PubMed ID: 31759951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA.
    Onidani K; Shoji H; Kakizaki T; Yoshimoto S; Okaya S; Miura N; Sekikawa S; Furuta K; Lim CT; Shibahara T; Boku N; Kato K; Honda K
    Cancer Sci; 2019 Aug; 110(8):2590-2599. PubMed ID: 31169336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unlocking the future of cancer diagnosis - promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer.
    Reina C; Šabanović B; Lazzari C; Gregorc V; Heeschen C
    Transl Res; 2024 Oct; 272():41-53. PubMed ID: 38838851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.